MiNA Therapeutics Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 18
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $30.3M
Latest Deal Amount
  • Investors
  • 4

MiNA Therapeutics General Information

Description

Developer of therapeutic medicines designed to harness gene activation mechanisms through small activating RNA. The company's technology and clinical know-how transform the therapy landscape of cancer and other severe diseases, enabling doctors and physicians to cure cancer and other severe diseases and develop new medicines that restore normal function to patients' cells.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Translation & Innovation Hub
  • 80 Wood Lane
  • London W12 0BZ
  • England, United Kingdom

MiNA Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

MiNA Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 10-Sep-2020 $30.3M 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC 11-Sep-2019 000.00 000.00 00000 Completed Clinical Trials - Phase 1
3. Corporate 02-May-2017 000.00 000.00 00000 Completed Clinical Trials - Phase 1
2. Later Stage VC 18-Jul-2016 $2.26M $3.23M 000.00 Completed Pre-Clinical Trials
1. Seed Round 10-Apr-2015 $972K $972K 000.00 Completed Pre-Clinical Trials
To view MiNA Therapeutics’s complete valuation and funding history, request access »

MiNA Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series N 0,000 00.000000 000.00 000.00 00 000.00 0.00
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
Series N 00,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 101,192 $0.000122 $20.25 $20.25 1x $20.25 5.62%
Ordinary 292,770 $0.000122 $18.74 $18.74 1x $18.74 16.27%
To view MiNA Therapeutics’s complete cap table history, request access »

MiNA Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Robert Habib Chief Executive Officer & Board Member
David Blakey Chief Scientific Officer
John Rossi Ph.D Co-Founder & Scientific Advisory Board Member
Pål Sætrom Ph.D Co-Founder & Member of Scientific Advisory Board
Nagy Habib MD Co-Founder, Chairman & Head, Research & Development
To view MiNA Therapeutics’s complete executive team members history, request access »

MiNA Therapeutics Board Members (7)

Name Representing Role Since
Christopher Wood MD Self Board Member 000 0000
Gur Roshwalb MD aMoon Fund Board Member 000 0000
Kieran Johnson Self Board Member 000 0000
Nagy Habib MD MiNA Therapeutics Co-Founder, Chairman & Head, Research & Development 000 0000
Peter Bains Sosei Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

MiNA Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MiNA Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
aMoon Fund Venture Capital Minority 000 0000 000000 0
Golden Triangle Partners Venture Capital Minority 000 0000 000000 0
Sosei Corporation Minority 000 0000 000000 0
Galloway VC-Backed Company Minority 000 0000 000000 0
To view MiNA Therapeutics’s complete investors history, request access »